Lisa M Gudenkauf, Melody Chavez, Melinda L Maconi, Carley Geiss, Ameen Seyedroudbari, Pan Thin, Aasha I Hoogland, Kathleen Nguyen, Vishnu Murthy, Wesley R Armstrong, Khaled Komrokji, Laura B Oswald, Heather S L Jim, Ghassan El-Haddad, Wolfgang Peter Fendler, Ken Herrmann, David Cella, Johannes Czernin, Michael S Hofman, Adam P Dicker, Jeremie Calais, Scott T Tagawa, Brian D Gonzalez
The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly with recent FDA approval of the first Lutetium-177-PSMA-ligand. Current patient-reported outcomes (PRO) measures were designed to assess impacts of chemotherapy or surgery. We aimed to develop the first PRO measure for PC patients receiving RNT. Methods: First, we identified relevant symptoms/toxicities by reviewing published trials and interviews with PC patients receiving RNT ( n = 29), caregivers ( n = 14), and clinicians ( n = 11)...
January 12, 2023: Journal of Nuclear Medicine